Targeted therapy in non-small-cell lung cancer--is it becoming a reality? (Q37765472)

22 August 2017

1 reference

title

Targeted therapy in non-small-cell lung cancer--is it becoming a reality? (English)

1 reference

22 August 2017

Razelle Kurzrock

1 reference

22 August 2017

Filip Janku

1 reference

22 August 2017

David J Stewart

1 reference

22 August 2017

language of work or name

English

0 references

publication date

15 June 2010

1 reference

Nature Reviews Clinical Oncology

22 August 2017

published in

1 reference

22 August 2017

1 reference

22 August 2017

1 reference

22 August 2017

page(s)

401-414

1 reference

Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung cancer

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

Randomized phase II trial of pemetrexed combined with either cisplatin or carboplatin in untreated extensive-stage small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

MEK and EGFR inhibition demonstrate synergistic activity in EGFR-dependent NSCLC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

Lung cancer in never smokers: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

Chemotherapy in non-small cell lung cancer: an update of an individual patient data-based meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: a phase III randomized trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

Epidermal growth factor-related peptides and their receptors in human malignancies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

A comparison of epidermal growth factor receptor levels and other prognostic parameters in non-small cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

ERBB receptors and cancer: the complexity of targeted inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

Erlotinib in previously treated non-small-cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR.21

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

Erlotinib in lung cancer - molecular and clinical predictors of outcome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

Detecting an overall survival benefit that is derived from progression-free survival

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

Schedule-dependent apoptosis in K-ras mutant non-small-cell lung cancer cell lines treated with docetaxel and erlotinib: rationale for pharmacodynamic separation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

Decitabine effect on tumor global DNA methylation and other parameters in a phase I trial in refractory solid tumors and lymphomas.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

Survival of cancer cells is maintained by EGFR independent of its kinase activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

Screening for epidermal growth factor receptor mutations in lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

A multicentre phase II gene expression profiling study of putative relationships between tumour biomarkers and clinical response with erlotinib in non-small-cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

Epidermal growth factor receptor immunohistochemistry: comparison of antibodies and cutoff points to predict benefit from gefitinib in a phase 3 placebo-controlled study in advanced nonsmall-cell lung cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

Cetuximab in combination with carboplatin and docetaxel for patients with metastatic or advanced-stage nonsmall cell lung cancer: a multicenter phase 2 study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

A randomized, phase II trial of two dose schedules of carboplatin/paclitaxel/cetuximab in stage IIIB/IV non-small-cell lung cancer (NSCLC)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

Randomized phase II study of gemcitabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

Sorafenib in advanced clear-cell renal-cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

Targeted therapy for metastatic renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

Sorafenib in advanced hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

Expression and distribution of insulin-like growth factor-1 receptor in human carcinomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

New concepts in regulation and function of the insulin-like growth factors: implications for understanding normal growth and neoplasia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

The prognostic significance of pretreatment plasma levels of insulin-like growth factor (IGF)-1, IGF-2, and IGF binding protein-3 in patients with advanced non-small cell lung cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

Promoter hypermethylation of resected bronchial margins: a field defect of changes?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

LKB1/KRAS mutant lung cancers constitute a genetic subset of NSCLC with increased sensitivity to MAPK and mTOR signalling inhibition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

Tobacco carcinogen-induced cellular transformation increases activation of the phosphatidylinositol 3'-kinase/Akt pathway in vitro and in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

PIK3CA mutations and copy number gains in human lung cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

PIK3CA gene amplification in Japanese non-small cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

PIK3CA mutation status in Japanese lung cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

Inhibition of mammalian target of rapamycin reverses alveolar epithelial neoplasia induced by oncogenic K-ras

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

MET as a target for treatment of chest tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

Uncommon tumors and exceptional therapies: paradox or paradigm?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

Cancer: the road to Amiens

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.64

Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression

31 March 2020

1 reference

12 December 2020

Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling

1 reference

12 December 2020

Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung

1 reference

12 December 2020

Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival.

1 reference

12 December 2020

Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group

1 reference

12 December 2020

10.1038/NRCLINONC.2010.64

Identifiers

DOI

1 reference

22 August 2017

1 reference